These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 2202770)
1. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770 [TBL] [Abstract][Full Text] [Related]
2. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311 [TBL] [Abstract][Full Text] [Related]
3. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers]. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385 [TBL] [Abstract][Full Text] [Related]
4. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nio Y; Tobe T Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435 [TBL] [Abstract][Full Text] [Related]
5. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774 [TBL] [Abstract][Full Text] [Related]
6. [Analysis of immunological response of regional lymph node lymphocytes from patients with gastric cancer after endoscopic local injection of biological response modifier (BRM)]. Obi Y Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):293-302. PubMed ID: 2051981 [TBL] [Abstract][Full Text] [Related]
7. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432]. Kobayashi G Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383 [TBL] [Abstract][Full Text] [Related]
8. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer]. Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507 [TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of gastric cancer]. Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771 [TBL] [Abstract][Full Text] [Related]
10. [Clinical trial of oral immunotherapy with streptococcal preparation OK 432 on gastric cancer]. Nio Y; Ohgaki K; Henmi K; Kan N; Inamoto T; Tsuchitani T; Kodama H; Tobe T Nihon Gan Chiryo Gakkai Shi; 1982 Apr; 17(3):728-34. PubMed ID: 6752308 [No Abstract] [Full Text] [Related]
11. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden. Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892 [TBL] [Abstract][Full Text] [Related]
12. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation. Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432 [TBL] [Abstract][Full Text] [Related]
13. [Preoperative immunotherapy in patients with gastric cancer--with special reference to analysis with monoclonal antibodies of T-lymphocyte subsets and interleukin-2 oral administration of OK-432 (Picibanil)]. Izumi M Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):27-32. PubMed ID: 8437550 [TBL] [Abstract][Full Text] [Related]
14. [Clinical study on the effect of adjuvant immunochemotherapy using OK-432 and 5-FU in pharyngeal and laryngeal cancers]. Yajin K; Harada Y; Tagashira N; Suzuki M; Hirakawa K; Sera K; Nakata M; Takebayashi S; Okazaki H; Yashiki T Gan To Kagaku Ryoho; 1988 Jun; 15(6):1921-7. PubMed ID: 3289502 [TBL] [Abstract][Full Text] [Related]
15. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study]. Yamamura Y; Yasue M; Nakazato H; Ota K Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941 [TBL] [Abstract][Full Text] [Related]
16. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432]. Yamada Y; Yamamoto K; Wakita K; Shiraki S; Noda K Gan To Kagaku Ryoho; 1986 Dec; 13(12):3427-31. PubMed ID: 3789753 [TBL] [Abstract][Full Text] [Related]
17. [A case of advanced gastric cancer responsive to intratumoral OK-432 injection]. Sakai Y; Maeda M; Koyama W; Totsuka S; Sakamoto S; Kanayama M Gan To Kagaku Ryoho; 1988 Jun; 15(6):1978-80. PubMed ID: 3382244 [TBL] [Abstract][Full Text] [Related]
18. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836 [TBL] [Abstract][Full Text] [Related]
19. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection]. Hosokawa T Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533 [TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation of intratumoral OK-432 administration]. Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]